1. Catalog
  2. Alcohol Use Disorder and Liver Transplantation – E ...
Alcohol Use Disorder and Liver Transplantation – Ethical, Medical, and Social Perspectives
Image For Activity Cover
Create Account
Availability
Registration Required
https://aasld.zoom.us/j/82660421818
May 21, 2025 12:00 PM - 1:00 PM ET
Cost
$0.00
Credit Offered
No Credit Offered
  • Description
  • Learning Objectives
  • Accreditation Information
  • Faculty
This webinar features a panel discussion to discuss the complex intersection of alcohol use disorder (AUD) and liver transplantation. This insightful conversation will explore the medical, ethical, and social challenges faced by healthcare professionals, patients, and policy makers in determining eligibility managing post-transplant care and addressing the stigma surrounding the issues.

This webinar is hosted by the American Association for the Study of Liver Diseases (AASLD).

AASLD is a PCSS-MAUD partner. Funding for this initiative was made possible by cooperative agreement no. 1H79TI086771-01 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
Upon completion of this activity, participants should be able to:

• Describe the evidence behind current practices related to liver transplantation for patients with alcohol use disorder and alcohol-
associated liver disease.
• Review post-transplant outcomes in patients with alcohol use disorder and alcohol-associated liver disease.
• Identify approaches to providing alcohol use disorder treatment for patients with alcohol-associated liver disease across the pre- and post-
transplant continuum
The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association for the Study of Liver Diseases designates this blended (live and enduring) activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Moderator: Lamia Hague, MD, MPH

Panelists: Scott Winder, MD, MSc, Brian Lee, MD Juan Pablo Arab, MD, FRCPC, Jessica Mellinger, MD
Powered By